Morgan Stanley
WX

Morgan Stanley’s WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS WX Stock Holding History

Morgan Stanley’s Portfolio WX Stock Details WX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-488,642
Closed -$21.1M – 7019
2015
Q3 		$21.1M Buy
488,642
+185,474
+61% +$7.83M 0.01% 1330
2015
Q2 		$12.8M Buy
303,168
+186,271
+159% +$7.86M ﹤0.01% 1868
2015
Q1 		$4.53M Sell
116,897
-13,913
-11% -$536K ﹤0.01% 2846
2014
Q4 		$4.4M Sell
130,810
-126,658
-49% -$4.47M ﹤0.01% 2849
2014
Q3 		$9.02M Buy
257,468
+54,278
+27% +$1.86M ﹤0.01% 2122
2014
Q2 		$6.68M Sell
203,190
-127,892
-39% -$4.38M ﹤0.01% 2405
2014
Q1 		$12.2M Buy
331,082
+213,912
+183% +$7.85M 0.01% 1793
2013
Q4 		$4.5M Buy
117,170
+20,470
+21% +$646K ﹤0.01% 2670
2013
Q3 		$2.65M Sell
96,700
-2,453
-2% -$58.1K ﹤0.01% 2999
2013
Q2 		$2.08M Buy
+99,153
New +$1.94M ﹤0.01% 3121

Other funds holding WX

Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return
CCS
Crosspoint Capital Strategies Orinda, California $50.4M AUM 15.37% 1-Year Est. Return

Morgan Stanley's WX Position: Q4 2015 in Review

Morgan Stanley sold out of WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS (WX) in Q4 2015, closing a stake of 488,642 shares — an estimated $21.1M sold.

Morgan Stanley first reported a position in WX in Q2 2013 and held it in 10 quarters. The position peaked at $21.1M in Q3 2015. 2 funds tracked by Wall St. Rank hold WX as of Q4 2015.

  • Morgan Stanley reported no remaining WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS position as of Q4 2015 after selling out during the quarter.
  • Morgan Stanley sold 488,642 WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS shares in Q4 2015, an estimated $21.1M.
  • Morgan Stanley first reported a position in WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS in Q2 2013 and held it in 10 quarters.
  • Morgan Stanley's WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS position peaked at $21.1M in Q3 2015.
  • 2 funds tracked by Wall St. Rank held WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS as of Q4 2015.

Based on Morgan Stanley's 13F filing for Q4 2015, filed 9 Feb 2016.